Integrating Immunotherapy Into Clinical Practice: Changes Over the Past Year in GI Oncology

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Disclosures

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Anti-PD1 Therapy in 20+ Tumor Types (Pembrolizumab)

Presented By Michael Morse at 2018 ASCO Annual Meeting

 MSI-H metastatic colorectal cancer

Presented By Michael Morse at 2018 ASCO Annual Meeting

 dMMR / MSI-high CRC: neoantigens and T cell infiltrate

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Slide 6

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Response in MSI-H nonCRC

Presented By Michael Morse at 2018 ASCO Annual Meeting

 CheckMate-142 Nivolumab +/- ipilimumab in dMMR/MSI-H mCRC

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Slide 9

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Slide 10

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Slide 11

Presented By Michael Morse at 2018 ASCO Annual Meeting

 MSS colon cancer……. still looking

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Metastatic colorectal cancer

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Gastroesophageal cancer

Presented By Michael Morse at 2018 ASCO Annual Meeting

KEYNOTE-059 cohort 1: Efficacy and Safety of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric Cancer

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Response in All Patients

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Keynote 059 Phase II 3L+ single arm study:<br />Response by PD-L1 Expression

Presented By Michael Morse at 2018 ASCO Annual Meeting

 PD-L1 Expression IHC*

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Progression-Free Survival

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Overall Survival

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Pembrolizumab vs SOC 2L<br />Phase III KEYNOTE-061

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Avelumab vs SOC 3L<br />Phase III Javelin-300

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Pembrolizumab in esophageal cancer: Keynote 180

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Integrating checkpoint blockade into management of Gastroesophageal cancers

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Hepatocellular carcinoma

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Nivolumab in Sorafenib-Experienced Patients With HCC ± HCV or HBV

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Nivolumab in Sorafenib-Experienced Patients: Efficacy

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Nivolumab in Sorafenib-Experienced Pts: Well tolerated <br />

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Pembrolizumab after sorafenib: Keynote-224

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Slide 6

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Responses regardless of hepatitis status

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Progression-free and Overall Survival

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Treatment-related Adverse Events

Presented By Michael Morse at 2018 ASCO Annual Meeting

 How to incorporate: Sorafenib-pretreated HCC

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Slide 35

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Anal squamous cell Ca

Presented By Michael Morse at 2018 ASCO Annual Meeting

 NCI9673: Phase II Nivolumab in Metastatic Anal Cancer

Presented By Michael Morse at 2018 ASCO Annual Meeting

 NCI9673: PFS, OS, Toxicity

Presented By Michael Morse at 2018 ASCO Annual Meeting

 KEYNOTE-028: Phase Ib of Pembrolizumab for Recurrent Anal Cancer

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Incorporating checkpoint blockade into management

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Biliary tract malignancy

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Targets in BTC

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Pancreatic cancer

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Pancreatic Carcinoma: Immune Checkpoints <br />

Presented By Michael Morse at 2018 ASCO Annual Meeting

 Summary

Presented By Michael Morse at 2018 ASCO Annual Meeting